CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +2.7% · netto nieuwe posities -4.5% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 138 | -1 | 45.11M | $10.22B | +6 | −8 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | n/a |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | n/a |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | n/a | −1 |
| Q2 2024 | 14 | n/a | 3.92M | $810.09M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 5.84M | +0.5% | $913.69M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passief) | 3.86M | +5.5% | $603.32M | 0.0% | ▲ Add | 2 | SEC ↗ ×18 |
| 3 | Wellington Management ✦ | 3.19M | -15.3% | $499.18M | 0.1% | ▼ Trim | 6 | SEC ↗ ×8 |
| 4 | State Street Global Advisors ✦ (passief) | 1.83M | -1.5% | $286.50M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Harris Associates (Oakmark) ✦ | 1.47M | +26.7% | $230.48M | 0.4% | ▲ Add | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passief) | 1.27M | +2.8% | $197.82M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 959.54K | +58.1% | $150.13M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | Morgan Stanley ✦ | 834.79K | n/a | $130.61M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 9 | Arrowstreet Capital ✦ | 769.44K | +33.0% | $120.39M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 10 | JPMorgan Chase ✦ | 634.36K | n/a | $99.25M | 0.0% | n/c | 1 | SEC ↗ ×26 |
| 11 | Millennium Management ✦ | 465.10K | -8.3% | $72.77M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 12 | Fidelity (FMR) ✦ | 413.53K | +428.0% | $64.70M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 13 | Gotham Asset Management ✦ | 315.75K | +17.3% | $49.40M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 14 | PRIMECAP Management ✦ | 270.54K | 0.0% | $42.33M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 265.08K | +890.7% | $39.52M | 0.0% | ▲ Add | 6 | SEC ↗ ×6 |
| 16 | Goldman Sachs Group ✦ | 239.21K | n/a | $37.43M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 17 | Marshall Wace ✦ | 138.11K | +881.5% | $21.61M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 18 | Adage Capital Partners ✦ | 134.53K | +199.0% | $21.05M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 118.03K | -79.1% | $18.47M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 20 | T. Rowe Price ✦ | 72.86K | -2.2% | $11.40M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Two Sigma Investments ✦ | 67.76K | -27.7% | $10.60M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | Bridgewater Associates ✦ | 19.91K | Nieuw | $3.11M | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Bridgewater Associates | $3.11M | 0.0% |
Verlaten
| Norges Bank | $76.95M | was 0.0% |
| Point72 Asset Management | $35.87M | was 0.1% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 555 houders, 56.84M aandelen, $9.32B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Officer · EVP & Chief Financial… · 10 aand @ 297.43 · $2,974
Open-market verkopen (S)
Officer · 981 aand · $302,580
Director · 33.56K aand · $10.07M
Officer · 2.04K aand · $599,711
Director · 573 aand · $163,443
Officer, Director · 6.50K aand · $1.82M
Officer · 3.71K aand · $1.04M
Director · 28.73K aand · $7.90M
Officer · 620 aand · $163,643
Officer · 482 aand · $127,812
Officer · 404 aand · $104,446
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie